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Table 1
Characteristics of vaginal samples from Portuguese women (n = 260).a
Characteristic Gardnerella vaginalis positive (n = 96) Gardnerella vaginalis negative (n = 164)
Age, y 33 ± 11 31 ± 12
Previously diagnosed with bacterial vaginosis 23 (24.0) 29 (17.7)
Diagnosed with bacterial vaginosis more than once 10 (10.4) 13 (7.9)
Current symptoms
Itching 13 (13.5) 11 (6.7)
Pain 4 (4.2) 8 (4.9)
Increased vaginal discharge 9 (9.4) 17 (10.4)
Odor 13 (13.5) 9 (5.5)
Burning 12 (12.5) 11 (6.7)
Smoker 15 (15.6) 26 (15.9)
Chronic disease 23 (24.0) 33 (20.1)
Tampon user 41 (42.7) 82 (50.0)
Contraception
No answer 0 (0.0) 4 (2.4)
No contraception 16 (16.7) 30 (18.3)
Pill 62 (64.6) 92 (56.1)
Condom 15 (15.6) 43 (26.2)
Other 13 (13.5) 25 (15.2)
Change in sexual partner in the past 3 months 2 (2.1) 9 (5.5)
Children 34 (35.4) 52 (31.7)
Premature children 2 (2.1) 3 (1.8)
Presence of Atopobium vaginaeb 23 (24.0) 7 (4.3)
a Values are given as mean ± SD or number (percentage).
b Factor associated with significant difference between groups (P b 0.05).
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Cancer antigen 125 (CA-125) is a glycoprotein found on the surface
of cells originating from embryonic coelomic epithelium, including
epithelium of the fallopian tubes, endometrium, and endocervix [1].
Many causes of abdominopelvic inflammation have been associated
with elevations in CA-125 levels, including pelvic inflammatory disease
of which endometritis is a component [2]. Levonorgestrel intrauterine
devices (IUDs) have been associated with endometrial stromal leuko-
cytic infiltrates, focal necrosis, and scarring [3]. The present study was
conducted to determine the effect of levonorgestrel IUD placement on
CA-125 levels in healthy women of reproductive age.
Healthy premenopausal women aged 18–50 years seeking a
levonorgestrel IUD (Mirena; Bayer HealthCare, Wayne, NJ, USA) for
contraception at a single academic hospital in Ann Arbor, MI, USA,
between January 10, 2011, and January 9, 2012, were recruited.
Exclusion criteria included suspected endometriosis, known
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endometriosis or adenomyosis, irregular menstrual periods, history
of malignancy, any inflammatory process of the pleura or peritone-
um, pregnancy within the previous 12 weeks, IUD placement within
the previous 12 weeks, or known adnexal mass. Women who were
unable to undergo pre-insertion blood draw at least 3 days remote
from recent or expected menses were also excluded. The study
was approved by the institutional review board at the University of
Michigan. All participants provided written informed consent.
Prior to IUD insertion, a blood sample was taken; a repeat sample
was drawn 12 weeks after placement. Vaginal bleeding around the sec-
ond blood draw was recorded. Compensation (US $10) was provided
per completed blood draw. Blood samples were analyzed using the
ADVIA CA 125II chemiluminescent immunoassay (Siemens Healthcare
Diagnostics, Deerfield, IL, USA). Demographics were collected from
hospital records.
Power calculations revealed that 13 patients would be required to
show a difference in CA-125 of 5 U/mL using a 2-tailed test, assuming
a baseline CA-125 level of 10 U/mL at 90% power. Data were analyzed
using SPSS version 20 (IBM,Armonk, NY, USA); paired t test andPearson
correlationwere used for analysis as appropriate. Statistical significance
was determined at the 0.05 level.
Sixteen women were recruited, all of whom completed the pre-
insertion blood draw. The mean age of the participants was
30 ± 8 years (range, 19–50 years). Body mass index (BMI, calculated
as weight in kilograms divided by the square of height in meters)
ranged from 17.5 to 38.6, with mean of 23.9 ± 5.8. Mean gravidity
was 2.0 ± 2.5 and mean parity was 1.9 ± 2.8. The majority of the
women identified as white (n = 13), while 2 identified as South
Asian and 1 as Hispanic. None of the participants reported current to-
bacco use. Intrauterine device placement was ceased in 1 patient
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owing to cervical stenosis, and 2 women were lost to follow-up; the
remaining 13 participants completed the study.
Meanpre-insertionCA-125was10.7 ± 5.9 U/mL (range, 3.3–22 U/mL),
while mean post-placement CA-125 was 8.5 ± 4.2 U/mL (range,
2.8–18.5 U/mL) (Table 1); no significant difference was found be-
tween these values (P = 0.124). Moderate or severe dysmenorrhea
was present in 6 women; it was not associated with higher pre-
insertion CA-125 (11.3 vs 10.0 U/mL; P = 0.675). Bleeding within
3 days of the post-placement blood draw was documented in 4
participants; it was significantly associated with higher post-
placement CA-125 (12.3 vs 6.8 U/mL; P = 0.022). Mean time from
levonorgestrel IUD placement to post-placement blood draw was
14.7 ± 2.8 weeks (range, 12.1–22.4 weeks). No correlation was
found between any measure of CA-125 and age, BMI, gravidity,
or parity.
Given the focal endometrial inflammation and necrosis seen with
levonorgestrel IUDs throughout the time that they remain in situ [3],
we would have expected a small increase in serum CA-125 when con-
trolling for other known variables. However, the study failed to show
such a finding. Instead, average pre- and post-IUD placement CA-125
levels were statistically similar. This indicates that a simple mechanism
for CA-125 release into serum as a result of necrosis or inflammation of
the endometrium does not account for the observed physiology in this
population. Using ±3 days to control for bleeding at the time of the
post-placement blood draw was arbitrarily determined but it did
demonstrate utility in differentiating the effect of vaginal bleeding
on serum CA-125. The only other study to have examined serum
CA-125 levels in healthy women with IUD placement involved the
copper IUD [4]. The findings from that study demonstrated a signifi-
cant decrease in CA-125 after placement [4]. However, both pre- and
post-placement CA-125 levels were measured during menstruation,
and the average pre-insertion CA-125 level was higher than reported
in other studies.
In the present study, consistent with results from other investiga-
tions [4], CA-125 levels in healthy women did not significantly increase
with IUD placement, despite being elevated in women with pelvic
inflammatory disease. Based on these results, it appears that isolated
coelomic epithelial inflammation of endometrial origin as caused by
IUDs does not result in an elevation of serum CA-125 in otherwise
healthy women.
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Table 1
Serum CA-125.
CA-125 measurement Mean ± SD (range)
Pre-insertion, U/mL (n = 16) 10.7 ± 5.9 (3.3–22)
Post-placement, U/mL (n = 13) 8.5 ± 4.2 (2.8–18.5)
Difference, U/mLa (n = 13) –2.2 ± 4.8 (–12 to 3.9)
Abbreviation: CA-125, cancer antigen 125.
a Pre-insertion CA-125 subtracted from post-placement CA-125.
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